TIMI 10B

OBJECTIVE: To compare the angiographic efficacy and safety of several doses of TNK with front loaded rtPA for the treatment of ST elevation myocardial infarction.

View/Download
_______________________________________________________________________________

  1. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Cannon CP, McCabe CH, Gibson CM, et al. Circulation 1997;95:351-6.
    | Abstract | Request Reprints |

  2. Use of the TIMI frame count to compare flow at 90 min. after t-PA vs. TNK administration. Gibson M, McLean C, Rizzo MJ, Martin NE, Marble SJ, Dotani I, McCabe CH, Cannon CP, Braunwald E, for the TIMI 10 Investigators. Circulation 1996;94[Suppl. I]:I-89.
    | Request Reprints |

  3. Adjunctive stenting following thrombolysis in TIMI 10A & B. Gibson M, Rizzo MJ, McLean C, Sparano AM, Ryan K, Moynihan J, Ralston A, Dodge T, Cannon CP, Braunwald E. Circulation 1997;96(Suppl. I):I-328.
    | Request Reprints |

  4. A randomized comparison of TPA with TNK using the TIMI Frame Count: Results of TIMI 10B. Gibson M, Cannon CP, McCabe CH, Van de Werf FJ, Braunwald E. Circulation 1997;96(Suppl. I):I-330-I-331. | Request Reprints |

  5. Relationship between proximal and distal lesion location and baseline ST-segment changes in acute myocardial infarction. Goel M, Rizzo MJ, Syed J, Dodge JT, Al Mousa E, Marble SJ, Coulter SA. Circulation 1998;98:I-79.
    | Request Reprints |

  6. Outcomes of adjunctive PTCA/stenting for TIMI grade 2 flow following thrombolysis. Gibson M, Schweiger M, Sequeira RF, Frey M, Cannon CP, Williams DO, Van de Werf F, Braunwald E, for the TIMI 10B Study Group. J Am Coll Cardiol 1998;31(Suppl. A):231A.
    | Request Reprints |

  7. Flow distal and not proximal to the lesion is a correlate of clinical outcomes after thrombolysis. Gibson M, Sparano A, Ryan K, Moynihan J, Kelley M, Rizzo M, Marble S, McCabe C, Dodge T, Cannon CP, TIMI 10B Study Group. J Am Coll Cardiol 1998;31 (Suppl A):492A.
    | Request Reprints |

  8. A new angiographic method to calculate coronary artery velocity and its relationship to clinical outcomes after thrombolysis. Gibson M, Sparano A, Ryan K, Rizzo M, Kelley M, Marble S, Dodge T, Cannon CP, Braunwald E, for the TIMI 10B Investigators. J Am Coll Cardiol 1998;31 (Suppl A):12A.
    | Request Reprints |

  9. The range of QCA velocities for TIMI grades 2 and 3 flow. Moynihan J, Ryan K, Sparano A, Kelly M, Rizzo M, Marble S, Cannon CP, McCabe CH, Gobson M, for the TIMI 10A & B Study Group. J Am Coll Cardiol 1998;31(Suppl. A):11A.
    | Request Reprints |

  10. Earlier time to treatment is associated with improved coronary blood flow in acute MI. Rizzo MJ, Ryan KA, Kelley MB, Moynihan J, Cannon CP, Braunwald E. Circulation 1998;98 (Suppl I):I-698.
    | Request Reprints |

  11. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Gibson CM, Cannon CP, Murphy SA, et al. Am J Cardiol 1999;84:976-80.
    | Abstract | Request Reprints |

  12. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Gibson CM, Murphy SA, Rizzo MJ, et al. Circulation 1999;99:1945-50.
    | Abstract | Request Reprints |


  13. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. Gibson CM, Ryan KA, Kelley M, et al. Am Heart J 1999;137:1179-84.
    | Abstract | Request Reprints |

  14. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. Tanasijevic MJ, Cannon CP, Antman EM, et al. J Am Coll Cardiol 1999;34:739-47.
    | Abstract | Request Reprints |

  15. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Circulation 2000;102:2329-34.
    | Abstract | Request Reprints |

  16. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Gibson CM, Cannon CP, Murphy SA, et al. Circulation 2000;101:125-30.
    | Abstract | Request Reprints |

  17. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. Gibson CM, Anshelevich M, Murphy S, et al. Am J Cardiol 2000;86:1378-9, A5.
    | Abstract | Request Reprints |

  18. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. Modi NB, Fox NL, Clow FW, et al. J Clin Pharmacol 2000;40:508-15.
    | Abstract | Request Reprints |

  19. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Gibson CM, Marble SJ. Clin Cardiol 2001;24:577-84.
    | Abstract | Request Reprints |

  20. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Giugliano RP, McCabe CH, Antman EM, et al. Am Heart J 2001;141:742-50.
    | Abstract | Request Reprints |

  21. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Schweiger MJ, Cannon CP, Murphy SA, et al. Am J Cardiol 2001;88:831-6.
    | Abstract | Request Reprints |

  22. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Srinivas VS, Cannon CP, Gibson CM, et al. Am Heart J 2001;142:29-36.
    | Abstract | Request Reprints |

  23. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Circulation 2002;105:1909-13.
    | Abstract | Request Reprints |

  24. Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. Gibson CM, Chen M, Angeja BG, et al. J Thromb Thrombolysis 2002;13:9-12.
    | Abstract | Request Reprints |

  25. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Murphy SA, Gibson CM, Van de Werf F, McCabe CH, Cannon CP. Am J Cardiol 2002;90:51-4.
    | Abstract | Request Reprints |

  26. Is recurrent myocardial infarction following thrombolytic administration associated with long-term mortality? Gibson CM, Murphy SA, James D, Wong GC, Cannon CP, Giugliano RP, Antman EM, Braunwald E. J Am Coll Cardiol 2002;35(Suppl A):280A.
    | Request Reprints |

 

 

 

 

Home | Trials | Core Laboratories | Services | Publications | Education | Funding | Contact Us |

© 2009 All Rights Reserved TIMI Study Group